Clinical DataClinical trials show that patients treated with Opzelura and povorcitinib experience significant improvements over placebo, highlighting the drugs' effectiveness.
Market PotentialAnalyst projects significant peak sales for topical Opzelura and oral JAK inhibitor povorcitinib, indicating a strong revenue potential overlooked by the market.
Product PipelineThe dermatology franchise is expanding with promising new data for treatments in areas with currently no approved therapy, potentially renewing revenue streams.